Genome Prices Hope, Not the New Denominator

Summary: 314130.KQ was still quoted around KRW 6,120 on the latest accessible May 29, 2026 public quote pages checked on June 3, 2026, even after almost all of a KRW 27.07 billion perpetual CB was converted into 8,548,956 common shares at KRW 3,025, with listing on May 21, 2026. Add the 1,040,118 third-party placement shares that listed on April 30, 2026 at KRW 6,730, and roughly 26.5% of the prior share base hit the cap table within one month. The market is still paying for platform optionality and ADC hope. The cap table is already telling a more dilutive story.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Short Genome & Company, `314130.KQ`	Korea low/mid-cap biotech / CB conversion overhang / placement supply	The stock was still around KRW 6,120 on the latest accessible May 29 quote pages even after 8.55 million perpetual-CB conversion shares listed on May 21 at a KRW 3,025 conversion price, plus 1.04 million placement shares listed on April 30 at KRW 6,730.	High on overhang facts and quote date references.	Immediate through post-listing digestion and the next operating update.	A move from KRW 6,120 to KRW 5,600 is -8.5%. A move to KRW 5,300 is -13.4%. That does not require thesis failure, only a lower anchor to the enlarged share count.	Strong. The live tape still sits far above the conversion line.	Borrow and short-interest data were not verified live.
2	Short PostPrime, `198A.T`	Japan low-price growth equity / third-party allotment / warrant line	PostPrime closed at JPY 150 on June 2, 2026 after announcing 2,098,000 new shares at JPY 143 and 37,970 fixed-price warrants struck at JPY 158, with maximum dilution of 57.5% if fully exercised.	High on TDnet and quote freshness.	Funding closes on June 10, 2026.	A dump from JPY 150 to JPY 142 is -5.3% if the brief financing pop fades and the market re-anchors toward the cash issue price.	Good, but the gap versus the cash issue is narrower than the Korean candidate.	The stock already traded down to JPY 148 recently, so part of the financing reset is visible.
3	Short Shiang Yi Biotech, `6676.TWO`	Taiwan low-cap healthcare / private placement discount	Public Taiwan quote pages still showed the stock around NT$13.90 on May 29, 2026, versus a NT$12 private-placement price fixed on May 7, 2026.	Medium. Pricing is fresh enough, but the tradeable float impact is slower.	Near-term only if the market trades the private round as validation.	A move from NT$13.90 back to NT$13.00 is -6.5%.	Moderate. Discount is visible.	Three-year transfer restrictions on the private placement make the near-term overhang less direct.

Selected opportunity: Short Genome & Company, 314130.KQ.

Why this one now: It has the largest fresh denominator shock relative to the current tape. The new stock is not hypothetical. The major block already listed on May 21, 2026. Yet the common was still quoted near KRW 6,120 on the latest accessible May 29 market pages checked in this run.

Why it can jump or dump more than 5% soon: A move from KRW 6,120 to KRW 5,600 is already -8.5%. That does not require a failed drug readout. It only requires the market to stop valuing the old float and start valuing the enlarged one.

What should surprise the reader: The surprise is not that Genome raised money. Small biotech does that all the time. The surprise is that the market still trades the common at roughly 2.0x the KRW 3,025 perpetual-CB conversion price after the conversion shares are already listed.

The Setup

Genome & Company is a Korean biotech that still trades on pipeline optionality, platform narrative, and the possibility that one of its programs or adjacent businesses can inflect fast enough to outrun dilution.

That is the bull story. The live cap table is harsher.

On April 30, 2026, Korean market coverage cited a KRX conversion filing showing that holders of the company's perpetual CB requested conversion of KRW 25.86 billion out of KRW 27.07 billion, producing 8,548,956 common shares at a conversion price of KRW 3,025. Those shares were due to list on May 21, 2026. The same report noted that the new block represented about 23.6% of the then-issued share count. It also noted that 1,040,118 third-party placement shares had already listed on April 30, 2026. Taken together, roughly 26.5% of the prior share base was added within one month. [1]

The stock did not trade as if that mattered enough. The latest accessible public quote pages checked in this run still showed 314130.KQ around KRW 6,120 on the May 29, 2026 close, with a same-day range roughly KRW 5,330 to KRW 6,320. [2][3]

The short case is not "the science is worthless." The short case is narrower. The common still reflects more hope than the new denominator justifies.

The Mispricing

The market appears to be pricing optionality, not overhang.

That distinction matters. Sophisticated capital accepted a KRW 3,025 conversion line for the large perpetual-CB block. A separate third-party placement in early April was done at KRW 6,730 for 1,040,118 new shares. [1][4]

The live common around KRW 6,120 therefore sits:

slightly below the April placement price, but
still roughly 102% above the CB conversion line that generated the much larger May 21 listing.

The variant perception is that the market is still treating the stock as if the key event is future platform value creation, while the more immediate event is that a large amount of stock has already become real.

Price

Item	Level / Fact	Timestamp	Source
Latest accessible quote reference	KRW 6,120	May 29, 2026 close, checked June 3, 2026	Investing.com and Kokstock quote pages [2][3]
Same-day range	KRW 5,330 to KRW 6,320	May 29, 2026	Investing.com historical-data snippet [2]
Perpetual-CB conversion price	KRW 3,025	Conversion disclosed April 30, 2026	Greened report citing KRX filing [1]
Perpetual-CB conversion shares	8,548,956 shares	Shares scheduled to list May 21, 2026	Greened report citing KRX filing [1]
Third-party placement shares	1,040,118 shares	Listed April 30, 2026	Greened report and Butler summary [1][4]
Third-party placement issue price	KRW 6,730	Board decision April 3, 2026	DigitalToday and Butler summary [4][5]

The market does not need to revisit KRW 3,025 for this short to work. It only needs to trade lower than a tape that still looks complacent about a large completed conversion.

Positioning

The positioning evidence is partial.

Known facts:

The big share-creation event already moved from filing into listed stock on May 21, 2026. [1]
Public quote pages showed enough turnover on May 29 to prove the stock is tradable, but not enough to make an 8.55 million share overhang feel trivial. [2][3]
A separate April placement already added another 1.04 million shares. [1][4]

Missing-data note:

I did not verify live borrow availability.
I did not verify current stock-loan fee, locate size, or current short interest.
I do not have sufficiently reliable real-time foreign-flow data for a tighter positioning call.

That missing data matters. The thesis is about denominator shock and supply, not about a verified short squeeze in reverse.

Catalyst

The catalyst path is mechanical rather than sensational.

The large conversion block has already listed. The market is now in the digestion phase, not the anticipation phase. [1]
The stock remains well above the KRW 3,025 conversion line, which gives sellers and marginal holders a visible lower anchor. [1][2][3]
The next operating or pipeline update can matter in two directions. Any sign that commercialization or pipeline progress is slower than the market wants can force the stock to trade the cap table first and the optionality second.

This is not a single binary date trade. It is a near-term repricing trade in the weeks after a major share increase.

Payoff Map

The clean expression is common stock, but only with confirmed borrow.

This is not an options-first setup. I did not verify a liquid listed options chain with usable spreads. The edge is in the common, or not at all.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case for the short	35%	KRW 4,700	+23.2% gross short payoff	1 to 6 weeks	The market re-anchors closer to post-conversion economics and optionality buyers fade	Medium
Base Case for the short	45%	KRW 5,300	+13.4% gross short payoff	Days to 6 weeks	The stock simply trades back toward the lower end of the recent range as the new supply settles	Medium
Bottom Case for the short	20%	KRW 7,000	-14.4% gross short loss	Days to 4 weeks	Traders treat the conversion as old news and buy the story ahead of a fresh pipeline or platform catalyst	Medium
Invalidation / Stop Condition	n/a	Sustained close above KRW 7,000 or fresh evidence that the market is correctly paying for a new fundamental leg	n/a	Immediate to 4 weeks	The market proves it is willing to value the company on upside optionality despite the new share base	Medium

Probability-weighted expected value: +11.3% gross short payoff before borrow, fees, commissions, slippage, and recalls.

Calculation: 35% × 23.2% + 45% × 13.4% + 20% × (-14.4%) = 8.12% + 6.03% - 2.88% = +11.27% gross.

Current market price / level: KRW 6,120

Timestamp: latest accessible public quote pages showing May 29, 2026 close, checked June 3, 2026.

Primary instrument: Genome & Company common shares, 314130.KQ.

Alternative expressions considered: Put options were rejected because I did not verify a liquid live chain. A pair trade against a Korea biotech basket was rejected because the live disagreement is issuer-specific cap-table expansion.

Confidence: Medium. The overhang is clear. The exact pace of digestion and borrow conditions are not.

What Would Prove This Wrong

This thesis fails if the market decisively decides that the post-financing balance sheet and platform optionality deserve a higher multiple despite the larger share count.

It also fails if a genuinely new high-quality catalyst arrives fast enough to make the conversion overhang look irrelevant. In small biotech, a strong clinical or licensing event can erase financing gravity for a time.

The trade is not valid without real borrow. If the short cannot be located, or if the fee is too punitive, the article remains useful but the trade expression does not.

Risk Audit

Strongest counterargument: The perpetual-CB holders may not dump mechanically, and the market may view the conversion as a balance-sheet cleanup rather than an overhang. If investors start focusing on platform or ADC upside again, the stock can rally in spite of the cap-table expansion.

Most fragile assumption: That the market will care more about the new denominator than about future platform optionality over the next several weeks.

What the market may already know: The conversion filing was public before the May 21 listing date. A stock still around KRW 6,120 after that fact is evidence that many market participants already looked through it.

What could make the trade lose money even if the thesis is directionally right: Timing. The stock can squeeze or drift higher first, especially if liquidity is tight or if biotech sentiment turns risk-on.

Liquidity / execution risks: Korea small/mid-cap biotech spreads, borrow uncertainty, buy-in risk, and slippage around catalyst headlines.

Leverage risks: None should be used here. The trade is a denominator reset, not a controlled arbitrage.

Information reliability risks: Quote references are public delayed pages. Borrow, lending fee, and holder intent were not verified live.

Invalidation trigger: Sustained close above KRW 7,000, or fresh operating or pipeline evidence strong enough to justify the market paying through the overhang.

Publish / revise / reject recommendation: Publish. This is the best short in the scoped JP/KR/HK/TW/SG screen because the supply event is recent, large, and already listed.

Best Trade Strategy

Direction: Short.

Preferred instrument: 314130.KQ common stock, only with confirmed borrow.

Common-stock stance: Preferred. The thesis is about the common still trading too richly relative to the enlarged share base.

Options stance: Options rejected because I did not verify a liquid live options chain.

Entry reference: Around KRW 6,120, based on the latest accessible public quote references showing the May 29, 2026 close, checked June 3, 2026. [2][3]

Take-profit framework: First cover zone KRW 5,300 to KRW 5,600. Deeper cover zone KRW 4,700 only if the market clearly starts valuing the post-conversion denominator instead of the pre-conversion story.

Stop / invalidation: Sustained close above KRW 7,000, or a fresh corporate update that materially improves the fundamental story faster than the overhang can matter.

Time horizon: Days to six weeks.

Execution risks: Hard-to-borrow, forced buy-in, gap risk on biotech headlines, and event-driven squeezes.

Do-not-trade conditions: Do not short without confirmed borrow. Do not short if borrow cost destroys the expected-value edge. Do not use leverage. Do not hold blindly through a major unexpected clinical or licensing headline.

Monitoring checklist:

Monitor	Why It Matters
New KRX or company share-capital updates	Confirms whether more stock is entering or the overhang is settling
Borrow availability and fee	Determines whether the thesis is actually tradable
Price behavior around KRW 5,600, KRW 5,300, and KRW 7,000	Defines near-term cover and invalidation zones
Next company operating or pipeline update	Can either speed up the re-anchor or overwhelm it
Volume versus the May 21 to May 29 post-listing period	Shows whether supply is being absorbed or distributed

Bottom Line

Genome & Company is the best short in this scoped Asia low/mid-cap screen because the live disagreement is not abstract. A large block of stock already converted at KRW 3,025 and listed on May 21, 2026. The common was still quoted near KRW 6,120 on the latest accessible May 29 pages checked in this run. That is a wide enough gap to matter, and recent enough to trade, if borrow exists.

Research Quality Scorecard

Criterion	Score	Evidence Note
Market disagreement	5	Clear conflict between current tape and a much lower fresh conversion line
Evidence base	4	Overhang facts and quote dates are current, but primary-source DART pages were less accessible than secondary reproductions
Positioning and flows	3	New share supply is clear; live borrow and short-interest data are missing
Catalyst path	4	Post-listing digestion and the next operating update create a visible closing mechanism
Payoff architecture	4	Base downside clears 5% with explicit invalidation
Invalidation discipline	5	Stop and thesis-break conditions are specific
Differentiated insight	5	The non-obvious point is that the market still prices the old float despite the new one
Client value	4	Useful even if borrow prevents execution
Total	34 / 40	Publishable deep-dive short note

Section 17 Quality Gate

Check	Answer
1. Is the mispricing specific?	Yes
2. Is there evidence beyond narrative?	Yes
3. Is the positioning claim supported or clearly labeled as uncertain?	Yes
4. Is there a catalyst or plausible closing mechanism?	Yes
5. Is the downside case described honestly?	Yes
6. Is the strongest counterargument included?	Yes
7. Is the article useful even if the trade is not taken?	Yes
8. Are all factual claims sourced or marked as unverified?	Yes
9. Does the article avoid hype?	Yes
10. Does the headline match the actual evidence?	Yes
11. Does the article explain why this is the best opportunity right now?	Yes
12. Does the article explain why the selected asset can plausibly jump or dump more than 5% soon, including direction, trigger, timeframe, and evidence quality?	Yes
13. Does the article identify what should surprise a sophisticated reader?	Yes
14. Does the article include top, base, and bottom targets with probabilities that add to 100%?	Yes
15. Does the main article file include its Research Quality Scorecard in a dedicated section?	Yes
16. Are all reader-facing tables kept as Markdown tables in the main article file?	Yes
17. If optional table images were explicitly requested, are they saved as separate packaging artifacts without replacing the main article Markdown tables?	Not applicable
18. If the task required an illustration prompt, is it included inline in the main article file rather than a separate file, with a subtle `The Mispricing Desk` watermark requirement?	Yes
19. Does the main article file include a `Best Trade Strategy` section with direction, preferred instrument, common-stock stance, options stance, TP, SL or invalidation, timeline, execution risks, do-not-trade conditions, monitoring checklist, and sourced live prices or explicit missing-data notes?	Yes
20. If the thesis uses technical signals, are they framed as timing/confirmation inputs rather than the sole thesis? Does the article still work if the technical signal is removed?	Yes
21. Unless the user explicitly scoped the geography, did the research explicitly screen U.S., Japan, broader Asia, and Europe / UK lanes?	Not applicable. User explicitly scoped JP/KR/HK/TW/SG low/mid-cap shorts
22. If the article uses Japan market as a lane or scope, did the screen explicitly prioritize local small-cap / mid-cap equities and names priced at or below `JPY 800 / share`?	Yes. The Japan screen did that, but the Korean candidate was stronger
23. If the user requested a live Substack finish, was the post actually created or updated in Substack, and was `substack_submission_log.txt` updated immediately with status, artifact state, URL, and blocker notes if any?	Not applicable

Sources

Source	Use
Greened, "지놈앤컴퍼니, 영구CB 854만주 보통주 전환 5월 오버행 주의보", April 30, 2026	Perpetual-CB conversion amount, 8,548,956 conversion shares, KRW 3,025 conversion price, May 21, 2026 listing date, and one-month share-supply math.
Investing.com historical data page for Genome & Company	Latest accessible quote reference showing KRW 6,120 close and KRW 5,330 to KRW 6,320 same-day range for May 29, 2026, checked in this run.
Kokstock quote page for 314130	Cross-check for the late-May quote and trading range reference.
Butler company summary for Genome & Company	April 1,040,118 third-party placement shares, placement size, and KRW 6,730 issue price summary.
DigitalToday reproduction of Genome & Company April 3, 2026 rights/placement disclosure	Cross-check for April placement size and KRW 6,730 issue price.
JPX TDnet filing for PostPrime third-party allotment and fixed-price warrants, May 25, 2026	Japan candidate screen: 2,098,000 shares at JPY 143, 37,970 warrants, and financing structure.
Nomura quote page for PostPrime	Japan candidate screen: JPY 150 close on June 2, 2026.
Taiwan BigGo finance item for Shiang Yi Biotech private placement	Taiwan candidate screen: private placement at NT$12.
HiStock quote page for Shiang Yi Biotech	Taiwan candidate screen: latest accessible quote near NT$13.90.

AI Illustration Prompt

Realistic, high-value, high-end editorial cover image for The Mispricing Desk: a cold Korean biotech capital-markets scene at night, with two objects in tension on a brushed steel table. On one side, a clean laboratory vial and development binder labeled GENOME and PIPELINE OPTION. On the other side, a heavy stack of newly printed stock certificates stamped 8,548,956 SHARES, KRW 3,025, and MAY 21 LISTING. Above them, a digital market tile glows 314130.KQ 6,120, visibly suspended too high over the fresh-share stack. Add a smaller secondary slip marked 1,040,118 shares at KRW 6,730 to show the earlier placement. Mood: forensic, skeptical, institutional, premium, restrained. Palette: surgical white, steel gray, muted teal, dim exchange red, and black glass. Style: Bloomberg Markets realism with Barron's discipline and The Economist cover clarity. No cartoon DNA strands, no generic rising chart, no meme aesthetics. Include a subtle but clear watermark or text treatment reading The Mispricing Desk.